Meda to acquire Rottapharm, creating a European specialty pharma leader
·The combined entity will have enhanced scale, reach and profitability with 2013 pro-forma revenue and EBITDA of SEK 18 billion (€1.9 billion)[1] and SEK 5 billion (€0.5 billion) respectively ·Acquisition for SEK 21.2 billion (€2.275 billion) including net debt of SEK 2.8 billion (approx. €300 million) implying an equity value of SEK 18.4 billion (€1.975 billion) ·Increases revenue